LSD Therapy

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022. For the period, total cash was equivalent to $154.5 million -compared to $133.5 million as of December 31,...

Holding company Blackhawk Growth Corp.(OTC: BLRZF)'s subsidiary company MindBio Therapeutics Pty Ltd shared the positive data gathered from its Phase 1 clinical trials microdosing LSD formulation in 80 healthy participants. A practical summary of the outcomes collected at this stage: microdoses...

In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. The emerging biotech BetterLife Pharma Inc. (OTCQB: BETRF) has filed an international PCT along with a U.S. patent application for the...

A new scientific publication recently came out in the Biological Psychiatry journal announcing that results of an ongoing Phase 2 study of LSD-assisted therapy for patients suffering from anxiety with or without life-threatening illnesses show encouraging drug effects. The trial was led by the...

This article by Elisabetta Fato was originally published on Microdose and appears here with permission. In a human-centered era where pollution threatens our planet’s well-being, the use of psychedelic substances with a focus on changing our relationship with the natural world could be a...